Data Now Available on Company Website Following 8-K Filing Data Demonstrate that Treatment with TFF TAC Prevents Lung Transplant Rejection at Only One-sixth of the Dose of Oral Tacrolimus and at...
Biocon Limited has received approval from the South African Health Products Regulatory Authority (SAHPRA) for its vertically integrated, complex drug product Tacrolimus capsule 0.5mg, 1mg and 5mg strengths, in South Africa. This is the Company's first approval in this Country.
New Gene Expression Analysis from Ongoing Phase 2 Study Provides Strong Biomarker Evidence that Treatment with TFF TAC Results in Normalization of Rejection-Related Genes TFF TAC Prevented Rejection...
Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to...
FORT WORTH, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug...
Enforcement Report - Week of March 1, 2023
Enforcement Report - Week of February 1, 2023
REGiMMUNE’s lead candidate to prevent graft-versus-host disease after stem cell transplants has passed its phase 2 trial, setting the Taiwan-based biotech up for a late-stage test.
Enforcement Report - Week of August 10, 2022
Enforcement Report - Week of June 15, 2022